Remdesivir, the much-talked-about experimental drug used to treat COVID-19 patients, has been conditionally approved by Europe's top health care regulator, becoming the first drug to be "recommended for authorization" on the continent. "Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the European Union", the press release read. Several pharmaceutical companies around the world are also racing to develop a vaccine for the virus. It administered via injection into a vein. The investigational antiviral drug remdesivir has been explored as a treatment for several indications, including Ebola, severe acute respiratory syndrome (SARS), Marburg, Middle East respiratory syndrome (MERS) - and most recently COVID-19. Regulators in the United States and Japan have already signed off on its use. This effect was not observed in patients with mild and moderate course of the disease: time to recovery was 5 days for both group of ramdevpir, and for the placebo group.
So far, the only drug that has reduced mortality in COVID-19 is dexamethasone, a low-priced generic steroid that cut the death rate for the most seriously-ill patients by 41% at 28 days in the large-scale RECOVERY trial.
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others. As of May 2020, there was no good evidence that remdesivir reduced mortality in people with COVID-19.
The treatment was the first to show improvement in trials on COVID-19 patients and has won approval for emergency use in severely ill patients in the United States and South Korea, and received full approval in Japan.
The company will send the first set of 20,000 vials in two equal lots of 10,000 each to Maharashtra, Delhi, Tamil Nadu, Gujarat and Hyderabad, Hetero Healthcare said in a statement. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened now due to accelerating Covid-19 infection rates.